Conference call on NicOx SA’s 2010 Half Year Financial Results

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - July 28, 2010) -

TO: Investors, Analysts and Journalists

WHAT: NicOx S.A. will release its 2010 half year financial results on July 30 before the opening of the market trading in France and will host a conference call at 3:00 pm CET.

WHO: Michele Garufi, Chairman and CEO

Eric Castaldi, Chief Financial Officer

Gavin Spencer, VP Business Development

WHEN: Friday July 30 - 3:00 pm CET (2:00 pm UK - 9:00 am EST)

Phone number: +44 (0)20 7138 0845 or +1 212 444 0895 (for conference call and Q&A session).

A presentation will be available on NicOx’s website: www.nicox.com.

A replay of the conference call will be available from July 30 at 6:00 pm CET until August 6 midnight. To listen to the replay, dial +44 (0) 20 7111 1244 or +1 347 366 9565 - Access code: 3771435?

Thanks to confirm your participation to Irène Lalande, Investor and Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / lalande@nicox.com

The Company notably draws the investors’ attention to the following risk factors:

- Risques liés à la dépendance de la Société à l’égard du naproxcinod (Risks related to the Company’s dependence on the success of its lead product naproxcinod)

- Risques commerciaux et développements cliniques (Clinical developments and commercial risk)

- Risques liés aux contraintes réglementaires et à la lenteur des procédures d’approbation (Risks linked to regulatory constraints and slow approval procedures)

- Manque de capacités dans les domaines de la vente et du marketing (Lack of sales and marketing capabilities)

- Incertitude relative aux prix des médicaments et aux régimes de remboursement, ainsi qu’en matière de réforme des régimes d’assurance maladie (Uncertainty on drug pricing and reimbursement policies and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NME) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first- in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti- inflammatory drug candidate developed for the relief of the signs and symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug Administration (FDA) provided a Complete Response Letter to the New Drug Application (NDA) for naproxcinod stating that it does not approve the naproxcinod application. The naproxcinod Marketing Authorization Application (MAA) submitted by NicOx in December 2009 is currently under review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide- donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of hypertension, cardiometabolic diseases, eye diseases and dermatological diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

This information is provided by HUGIN